The aim of the study was to investigate the efficacy and safety of inhaled loxapine compared with the intramuscular (IM) antipsychotic aripiprazole in acutely agitated patients with schizophrenia or bipolar I disorder. PLACID was an assessor-blind, parallel-group trial conducted in 23 centres in the Czech Republic, Germany, Spain, and Russia. Patients (aged 18-65 years) diagnosed with schizophrenia or bipolar I disorder experiencing acute agitation (Clinical Global Impression [CGI]-Severity score Z 4) while hospitalized or attending an emergency room were randomized to receive up to two doses of inhaled loxapine 9.1 mg or IM aripiprazole 9.75 mg (Z 2 h between doses) during the 24-h study period. The primary efficacy endpoint was time to response (CGI-Improvement score 1 [very much improved] or 2 [much improved]). The primary analysis included randomized patients who provided informed consent (full analysis set [FAS]); the safety analysis included all patients who received study medication. The FAS comprised 357 E-mail address: lsan@pssjd.org (L. San).
Introduction
Agitation is a multifactorial syndrome (Garriga et al., 2016) with a spectrum of features including restlessness, mental tension, and excitement that is often characterized by excessive or inappropriate motor or verbal activity with an emotional arousal element. Acute agitation is common in patients with schizophrenia or bipolar disorder (Garriga et al., 2016; Hankin et al., 2011; Nordstrom et al., 2012) and represents a serious, disruptive complication that can escalate rapidly and unpredictably to loss of control, aggression, and physical violence toward the patient themselves, other patients, and their carers (Citrome and Volavka, 2014; Huber et al., 2008; Nordstrom et al., 2012) . Early recognition and prompt intervention to calm agitated patients are crucial to prevent escalation.
Current best-practice recommendations for treating agitation suggest that acute agitation should be managed initially with non-pharmacologic methods of behaviour control including verbal de-escalation and environmental modification techniques that focus on engaging the patient and avoiding the need for physical restraint (Garriga et al., 2016; Wilson et al., 2012) . If agitation progresses, restraint and/or pharmacologic intervention may be required. Medication given to manage agitated patients ideally needs to be easily administered by a route that will not traumatize the patient, and have a rapid onset of action, sustained therapeutic effect, and acceptable safety profile (Garriga et al., 2016) . Antipsychotic agents administered alone or in combination with benzodiazepines are the most frequently used pharmacologic regimen for management of agitation associated with schizophrenia or bipolar disorder (Battaglia, 2005; Currier and Trenton, 2002; Currier et al., 2004) . Although oral administration is preferred, it may not achieve a sufficiently rapid onset of therapeutic effect. Intramuscular (IM) formulations of antipsychotics provide faster symptomatic relief than oral formulations but administration via this route may distress the patient (De Filippis et al., 2013; Hankin et al., 2011; Kwentus et al., 2012) . Inhaled formulations of antipsychotic agents, such as loxapine, offer a non-coercive, non-invasive alternative (Hankin et al., 2011; Spyker et al., 2010) , with the potential to provide a more rapid onset of effect than IM injection due to the pharmacokinetic profile (deep lung absorption and rapid transition to the systemic circulation).
Clinical trials with inhaled loxapine in agitated patients with schizophrenia or bipolar I disorder showed an onset of therapeutic effect as early as 10 min after dosing, which was maintained through 24 h (Alexza UK Ltd, 2013; Allen et al., 2011; De Filippis et al., 2013; Kwentus et al., 2012; Lesem et al., 2011) . The efficacy of inhaled loxapine for the management of agitation in such patients has been confirmed in placebo-controlled, phase 3 trials (Kwentus et al., 2012; Lesem et al., 2011; Popovic et al., 2015) and is supported by indirect comparisons with other antipsychotics (Dundar et al., 2016) . However, head-to-head comparisons with other antipsychotics, including those delivered via IM injection, are lacking.
The PLACID trial was undertaken to assess the efficacy and safety of inhaled loxapine compared with the IM antipsychotic aripiprazole in acutely agitated patients with schizophrenia or bipolar I disorder. The primary efficacy objective of the study was to evaluate the time to response after administration of inhaled loxapine or IM aripiprazole, with response defined as a Clinical Global ImpressionImprovement (CGI-I; Guy, 1976) score of 1 (very much improved) or 2 (much improved).
Experimental procedures

Study design
The PLACID study was a phase 3b, open-label, assessor-blind, randomized, active-controlled, prospective, parallel-group, multicentre clinical trial to assess the efficacy and safety of inhaled loxapine compared with IM aripiprazole in acutely agitated patients with schizophrenia or bipolar I disorder (Figure 1 ). The study was conducted at 23 centres in the Czech Republic, Germany, Spain, and Russia. The study protocol has been published previously (San et al., 2017) .
The PLACID study was conducted in accordance with independent ethics committee and International Conference on Harmonisation Good Clinical Practice Guidelines and all applicable European Community regulations regarding clinical safety-data management. All study centres provided a written and dated approval/favourable opinion from the relevant independent ethics committee.
Patients
The study population comprised patients aged 18-65 years with a confirmed diagnosis of schizophrenia or bipolar I disorder according to the Diagnostic and Statistical Manual of Mental Disorders (version 5) criteria (American Psychiatric Association, 2013) , who were experiencing an acute episode of agitation. Hospitalized patients and those presenting at a psychiatric or general emergency room were included. Eligible patients were judged to be clinically agitated if they presented with a score of Z4 on the CGI-Severity (CGI-S) scale (Guy, 1976) but were otherwise in good health.
Patients whose agitation was judged to be caused primarily by acute alcohol or drug intoxication/withdrawal and those considered to be at serious risk for suicide were excluded. Additional exclusion criteria included treatment within 1 h before study drug administration with benzodiazepines or other hypnotics, or oral or shortacting IM antipsychotics. Patients were also excluded if they: were pregnant or breastfeeding; had a history of or current significant hepatic, renal, gastroenterological, respiratory, cardiovascular, endocrine, neurologic, or hematologic disease; had acute respiratory signs or symptoms, or active airways disease.
All patients were required to provide written informed consent after receiving a complete description of the study. Any patient who withdrew consent after randomization was not included in the analysis. In Russia, the Czech Republic, and Germany, patients who were considered to be of impaired capacity to provide informed consent were excluded. In Spain, a proxy or deferred informed consent was possible.
Randomization and masking
The treatment administered to individual patients was determined by a block randomization schedule developed by Parexel (Perceptive eClinical Limited, Basingstoke, UK). Patients were randomized (1:1) to receive inhaled loxapine or IM aripiprazole, and randomization was stratified according to the patient's disease (schizophrenia or bipolar I disorder). If the patient was eligible for the study, the investigator contacted the interactive voice-response system to randomize a patient and assign the appropriate kit number.
As the two study treatments were administered by different routes, drug administration and clinical evaluation were carried out by different staff. Baseline and all post-treatment clinical assessments for a patient were conducted by the same assessor who was blinded to treatment allocation. Patients were instructed not to tell the blinded assessor which treatment they had received.
Procedures
Patients were randomly assigned to receive either inhaled loxapine 10 mg (Adasuve s , Ferrer Internacional, Spain; delivered dose 9.1 mg) using the hand-held, portable Staccato s delivery system (Ferrer Internacional, Spain) or IM aripiprazole 9.75 mg per 1.3 mL dose (Abilify s ; Bristol-Myers Squibb, UK). Patients received a maximum of two doses of study drug, with the second dose given at least 2 h after the first if, it was clinically required to aid subsidence of agitation or treat a recurrence. Patients were monitored for bronchospasm for at least 1 h after both doses.
Patients could receive rescue medication to treat agitation from 20 min after the second dose of study medication, if considered necessary by the investigator.
The severity of agitation at baseline was assessed using the CGI-S before randomization of the patient as part of the eligibility assessment. Eligible patients had a baseline score of Z 4. Baseline evaluations were done as close as possible to, and within 30 min before, administration of the first dose of study medication (Dose 1).
The post-treatment evaluation period started with administration of Dose 1 and continued for at least 4 h and for a maximum of 24 h after Dose 1 or until the end of the agitation episode, whichever occurred first. Patients were assessed using the CGI-I scale at 10 7 2, 20 7 2, 30 7 2, 50 7 2, 60 7 5, 90 7 5, and 120 7 5 min after Dose 1 by the same assessor who did the CGI-S baseline assessment. The blinded assessor also assessed the response to Item 14 of the Treatment Satisfaction Questionnaire for Medication (TSQM; Atkinson et al., 2004 ) ('Taking all into account, how satisfied or dissatisfied do you feel with the treatment?') at 2 and 24 h after Dose 1, or the end of the agitation episode, whichever occurred first.
Vital signs were assessed at baseline and at 1, 2, and 4 h post treatment. Adverse events were monitored throughout the poststudy evaluation period.
Outcomes
The primary efficacy endpoint was the time to response measured during the first 2 h after the first dose of study drug. Response to treatment was defined as a CGI-I score of 1 (very much improved) or 2 (much improved) and the time to response was the first timepoint at which a CGI-I score of 1 or 2 was reached. Patients without a response within 2 h were considered non-responders and the time to response was set at 4 h (2 h more than the maximum follow-up for this variable).
Secondary endpoints included the proportion of patients achieving a response to treatment and the CGI-I score achieved at 10, 20, 30, 50, 60, 90 , and 120 min after Dose 1; the number of patients who received one or two doses of study drug with and without rescue medication at any time between 4 and 24 h after Dose 1 (or up to the end of the agitation episode, whichever occurred first); time to second dose of study drug; rescue medication use; and satisfaction with treatment (evaluated using Item 14 of the TSQM). Safety and tolerability were assessed by the reporting of adverse events (AEs), physical examination, recording of vital signs, and recording of rescue medication use. 
Statistical analysis
The main analysis of the primary endpoint was performed using the theoretical time at which the assessments were made (i.e., 10, 20, 30, 50, 60, 90 , and 120 min after Dose 1); the same analysis was performed as a sensitivity analysis with the actual time of assessment. Comparison of time to response between the two treatment groups was performed using a Wilcoxon rank-sum test with a twosided significance level of 0.05. The median difference (95% CI) was estimated via the Hodges-Lehmann method based on the Wilcoxon rank-sum distribution. Kaplan-Meier curves of time to response and median time to response with 95% CIs were derived by treatment group. The Mantel-Haenszel log-rank test was conducted for sensitivity purposes. A Cox regression model was used to estimate hazard ratios (HRs) and their 95% CIs to support the results of the log-rank test. Secondary analyses were performed using two-group χ 2 tests and were exploratory in nature. Safety and tolerability data were presented descriptively; only the number (%) of subjects reporting one or more treatment-emergent AE was compared using Fisher's exact test. The primary analysis was conducted on the full analysis set (FAS), which comprised all randomized patients, regardless of whether the patients received any study medication. Any patient who failed to provide informed consent or who withdrew consent after randomization was excluded from the FAS. The safety set included all enrolled patients who had received at least one dose of study medication. All analyses were performed using SAS (version 9.4; SAS Institute Inc., Cary, NC, USA).
A sample size of 180 patients in each group was estimated to provide 90% power to demonstrate superiority of inhaled loxapine versus IM aripiprazole for the primary efficacy endpoint at a one-sided significance level of 0.025. Owing to the limited data available for the initial sample size estimation, a planned interim analysis was performed when approximately 50% of the sample had been recruited to estimate the effect size of the two study interventions and to assess the assumptions of the initial sample-size estimation and feasibility of a sample-size increase. No changes to the planned sample size were made following the interim analysis.
The PLACID study protocol was registered with the European Clinical Trials Database on October 31, 2014 (EudraCT number 2014-000456-29).
Results
In total, 372 patients aged 18-65 years with a confirmed diagnosis of schizophrenia or bipolar I disorder were screened between December 2, 2014, and October 31, 2016. Of these, 359 patients were randomized; 344 of 357 patients (96.4%) in the FAS completed the study according to the protocol ( Figure SF1 ). One patient in the IM aripiprazole group did not receive study medication and was excluded from the safety analysis. The groups were well matched but each displayed considerable within-group heterogeneity in terms of baseline agitation category and prior medications (Table 1) . During the study, 60 patients (33.5%) in the inhaled-loxapine group and 43 (24.2%) in the IM aripiprazole group took at least one concomitant medication (defined as a treatment that was ongoing when the first dose of study medication was administered or started after it was given). CGI-S = Clinical Global Impression-Severity; IM = intramuscular; SD, standard deviation. a Categories defined by CGI-S score: 4 = moderately agitated, 5 = markedly agitated, 6 or 7 = severely agitated. b Prior medication was defined as treatment started and stopped before the first dose of study medication was administered.
The median time to CGI-I response using the theoretical time The faster onset of action of inhaled-loxapine group was seen at the first assessment timepoint;14.0% of patients achieved a CGI-I response at 10 min compared with 3.9% in the IM aripiprazole group (p = 0.0009). There continued to be significantly more responders in the inhaled-loxapine group at every assessment timepoint up to 60 min after dosing (p o 0.05; Figure 3) . At 60 min, 69.8% of patients in the inhaled-loxapine group and 56.2% in the IM aripiprazole group had responded to treatment (p = 0.0075). At 2 h, a similar proportion of patients in both groups had achieved a CGI-I response (84.4% and 82.6% in the inhaled-loxapine and IM aripiprazole groups, respectively; p = 0.652). The proportion of patients achieving a CGI response at each timepoint is shown in Table ST1 and CGI-I scores at each timepoint are shown in Table ST2 .
Few patients required a second dose of medication (6.7% of those treated with inhaled loxapine and 9.6% of those treated with IM aripiprazole; p = 0.3249). The median and 95% CI were not estimable for the time from Dose 1 to Dose 2, however, the log-rank test did not show statistically significant differences ]; p = 0.3315). The mean time to second dose and the range are shown in Table  ST3 . One patient in the inhaled-loxapine group required rescue medication 150 min after Dose 1; but no patients in the IM aripiprazole group required rescue medication.
Significantly more (p = 0.0012) patients in the loxapine group (53.8%) than in the aripiprazole group (36.4%) were 'very satisfied' or 'extremely satisfied' with the treatment received, as assessed using Item 14 of the TSQM at 24 h after dosing.
AEs were reported by 32.4% of patients treated with inhaled loxapine and 27.7% of patients treated with IM aripiprazole (Table 2 ). The most commonly reported AEs by system organ class were those of the nervous system (23.5% and 19.2% of patients in the inhaled-loxapine and IM aripiprazole groups, respectively; p = 0.3661) followed by respiratory, thoracic, and mediastinal disorders (7.8% and 1.1% of patients, respectively; p = 0.0034). Somnolence was the most common nervous system treatment-emergent AE (TEAE), reported by approximately 14% of patients in both groups. Dysgeusia was more common in the inhaled-loxapine a Based on scheduled time of assessments. CGI-I = Clinical Global Impression-Improvement; IM = intramuscular. group (12.3% vs 0% for IM aripiprazole); dizziness affected more patients in the IM aripiprazole group (6.2% vs 2.2% for inhaled loxapine). All of these TEAEs were reported to be of mild or moderate intensity. The higher incidence of respiratory, thoracic, and mediastinal disorders in patients treated with inhaled loxapine was driven by the incidence of cough (3.9% vs 0% for IM aripiprazole) and throat irritation (2.2% vs 0%, respectively); all such events were classed as being of mild intensity. Two patients in the IM aripiprazole group experienced severe TEAEs (hallucination [n = 1] and aggravation of a general disorder/administration-site condition [n = 2]); both discontinued treatment due to the TEAEs. One patient in the inhaled-loxapine group experienced a serious TEAE (asthenia and dizziness); the patient recovered without discontinuing from the study. Although patients with active airways disease should have been excluded from participation in the study, four patients with asthma were enrolled and two were randomized to inhaled loxapine. Bronchospasm events were not reported in either of these patients. No deaths occurred during the study.
Discussion
The results of the PLACID study demonstrate that inhaled loxapine is superior to IM aripiprazole in terms of time to response and proportion of CGI-I responders during the first hour after drug administration in acutely agitated patients with schizophrenia or bipolar I disorder. These findings are especially relevant for the management of acute agitation in clinical practice as the study was designed to reflect the real-world setting as closely as possible.
In most clinical trials, the effect of an intervention is assessed in ideal circumstances. The results of such studies are of limited relevance in addressing whether an intervention is effective in real-life clinical practice, and thus are only of partial use to clinicians, managers, and policymakers (Tunis et al., 2003) . In a pragmatic clinical trial, such as PLACID, the patient population is representative of the people who will receive the treatment in clinical practice and the study is conducted in a setting typical of where such treatment will take place (Califf and Sugarman, 2015) . The PLACID study is the first head-to-head comparison of antipsychotic agents delivered via inhalation and IM injection for the management of acute agitation in patients with schizophrenia or bipolar I disorder, both in hospital and emergency settings. Reflecting real-life clinical practice, the patient population included in the study was heterogeneous in terms of underlying disease, baseline agitation level, and previous and concomitant treatments. IM aripiprazole is widely used in clinical practice to treat agitation episodes at the standard dose of 9.75 mg, with a possibility of two further doses over 24 h. IM aripiprazole was selected as the comparator to inhaled loxapine in the PLACID study because the IM route is known to provide rapid onset of efficacy; both drugs are indicated for agitation; the drugs act at similar receptors; and both are minimally sedative. Time to CGI-I response was significantly shorter and the proportion of responders was significantly higher during the first hour after drug administration in patients receiving inhaled loxapine compared with those receiving IM aripiprazole. These are clinically relevant findings because, until now, IM injection was considered the most rapid administration route (except for intravenous formulations that are used in limited situations and may require mechanical restraint of the patient). The observed response rate is consistent with the pharmacokinetic profile of inhaled loxapine, which is similar to that of the intravenous formulations, with a time to reach maximal plasma concentration of approximately 2 min (Pollack, 2016) . This pharmacokinetic profile results in rapid onset of effect compared with IM aripiprazole, as reflected in the significantly greater proportion of CGI-I responders with inhaled loxapine at the first assessment timepoint (10 min after treatment). These results confirm those reported previously with inhaled loxapine in agitated patients with schizophrenia or bipolar disorder (Kwentus et al., 2012) . Rapid reduction in agitation decreases the likelihood of the need for restraints, patient seclusion, and hospital admission. It may also avoid the prolonged hospitalization associated with the use of restraints (Richmond et al., 2012) .
Inhaled loxapine potentially offers another advantage over IM-administered antipsychotics. Optimal care for patients with agitation includes maintenance of the therapeutic alliance between the patient and their healthcare providers (Garriga et al., 2016; Hankin et al., 2011; Holloman and Zeller, 2012) . Patients who have not been restrained and forcibly medicated are less likely to mistrust and fear medical personnel and may feel more comfortable about seeking assistance in the future, hopefully before reaching a highly agitated state (Richmond et al., 2012 ). In the current study, significantly more patients treated with inhaled loxapine reported being 'very' or 'extremely' satisfied with their treatment compared with those treated with IM aripiprazole. Such levels of satisfaction suggest that the inhaled route of administration may help to preserve the patient-clinician relationship and encourage the patient's active participation in treatment decisions.
The safety profile of inhaled loxapine reported here is consistent with previous reports for this agent, with dizziness, dysgeusia, and somnolence being the most commonly reported AEs (Alexza UK Ltd, 2013; Allen et al., 2011; De Filippis et al., 2013; Kwentus et al., 2012; Lesem et al., 2011) . Reports of throat irritation were more common in patients treated with inhaled loxapine than those treated with IM aripiprazole. These events were of mild severity and resolved without clinical sequelae.
The study's strengths lie in the direct comparison with a commonly used IM antipsychotic and the applicability of the results to real-world clinical practice. This is the first controlled study of the onset of action of two pharmacologic agents for agitation. Head-to-head trials are rare and much needed in order to guide clinical practice. However, the study also has some limitations: its open-label design, with two treatments administered by different routes, meant that although the assessors were blinded to treatment allocation, this was a potential source of bias if the patients told the assessor which treatment they had received. It may have been possible for the assessor to guess the treatment because of the demeanour of the patient or the way they interacted with medical personnel as a result of distress caused during administration of the study medication. On the other hand, patient knowledge of their randomized treatment and that the comparator was administered via IM injection, may have induced a bias when assessing patient satisfaction with the treatment.
The CGI scale was used to assess agitation; while the authors acknowledge that this scale is not specific for agitation, unlike, for example, the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) (Kay et al., 1987) , the CGI scale captures clinical impressions that transcend symptom checklists. Although the PANSS-EC is the preferred assessment tool in clinical research and registration clinical studies, it is infrequently used in clinical practice because of the need for specific ratings knowledge and the administration time required. In contrast, the CGI scale is readily understandable and relatively easy to use in a clinical practice setting. Furthermore, CGI-I and PANSS-EC have shown good correlation in assessing agitation (Montoya et al., 2011) .
Agitation is associated with a number of psychiatric conditions, but the underlying pathophysiological mechanisms are similar (Garriga et al., 2016) . The PLACID study demonstrated that inhaled loxapine exhibits key features of an ideal medication to treat agitation in patients with schizophrenia or bipolar I disorder: it is easily administered via a non-invasive route; it has a rapid onset of action with a sustained therapeutic effect; and it has an acceptable safety profile (Garriga et al., 2016) . These results have implications for patients already hospitalized and those presenting at emergency departments with acute agitation (Zeller and Citrome, 2016) . Acutely agitated patients diagnosed with other psychiatric disorders may also benefit from the treatment with inhaled loxapine and could be considered for inclusion in future studies.
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